NGNE
$19.05-0.14 (-0.73%)
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Recent News
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene (NASDAQ:NGNE) CEO and founder Rachel McMinn outlined the company’s progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lea
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’ earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the ... Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim’s 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a “de
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...